You are here:Marin Noble's publications

Martin Noble's publications
    Shao H., Shi S., Huang S., Hole A., Abbas A.Y., Baumli S., Liu X., Lam F., Foley D.W., Fischer P.M., Noble M., Endicott J.A., Pepper C., Wang S. (2013) Substituted 4-(thiazol-5-yl)-2-(phenylamino)pyrimidines are highly active CDK9 inhibitors: synthesis, x-ray crystal structure, SAR and anti-cancer activities. J. Med. Chem. [Pubmed]
    Hole A., Baumli S., Shao H., Shi S., Pepper C., Fischer P.M., Wang S., Endicott J.A., Noble M. (2012) Comparative structural and functional studies of 4-(thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 inhibitors suggest the basis for isotype selectivity. J. Med. Chem. [Pubmed]
    Baumli S., Hole A.J., Wang L.Z., Noble M.E., Endicott J.A. (2012) The CDK9 tail determines the reaction pathway of positive transcription elongation factor b. Structure 20(10):1788-95. [Pubmed]
    Boehringer J., Riedinger C., Paraskevopoulos K., Johnson E.O., Lowe E.D., Khoudian C., Smith D., Noble M.E., Gordon C., Endicott J.A. (2012) Structural and functional characterization of Rpn12 identifies residues required for Rpn10 proteasome incorporation. Biochem. J. 448(1):55-65. [Pubmed]
    Endicott J.A., Noble M.E., Johnson L.N. (2012) The structural basis for control of eukaryotic protein kinases. Annu. Rev. Biochem. 81:587-613. [Pubmed]
    Baumli S., Hole A.J., Noble M.E., Endicott J.A. (2012) The CDK9 C-helix exhibits conformational plasticity that may explain the selectivity of CAN508. ACS Chem. Biol. 7(5):811-6. [Pubmed]
    Noble M., Ladbury J.E. (2011) Catalysis and regulation. Curr. Opin. Struct. Biol. 21(6):775-6. [Pubmed]
    Watson A.F., Liu J., Bennaceur K., Drummond C.J., Endicott J.A., Golding B.T., Griffin R.J., Haggerty K., Lu X., McDonnell J.M., Newell D.R., Noble M.E., Revill C.H., Riedinger C., Xu Q., Zhao Y., Lunec J., Hardcastle I.R. (2011) MDM2-p53 protein-protein interaction inhibitors: a-ring substituted isoindolinones. Bioorg. Med. Chem. Lett. 21(19):5916-9. [Pubmed]
    Sinclair J.C., Davies K.M., VĂ©nien-Bryan C., Noble M.E. (2011) Generation of protein lattices by fusing proteins with matching rotational symmetry. Nat. Nanotechnol. 6(9):558-62. [Pubmed]
    McNicholas S., Potterton E., Wilson K.S., Noble M.E. (2011) Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr. D Biol. Crystallogr. 67(Pt 4):386-94. [Pubmed]
    Hardcastle I.R., Liu J., Valeur E., Watson A., Ahmed S.U., Blackburn T.J., Bennaceur K., Clegg W., Drummond C., Endicott J.A., Golding B.T., Griffin R.J., Gruber J., Haggerty K., Harrington R.W., Hutton C., Kemp S., Lu X., McDonnell J.M., Newell D.R., Noble M.E., Payne S.L., Revill C.H., Riedinger C., Xu Q., Lunec J. (2011) Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J. Med. Chem. 54(5):1233-43. [Pubmed]
    Riedinger C., Noble M.E., Wright D.J., Mulks F., Hardcastle I.R., Endicott J.A., McDonnell J.M. (2011) Understanding small-molecule binding to MDM2: insights into structural effects of isoindolinone inhibitors from NMR spectroscopy. Chem. Biol. Drug. Des. 77(5):301-8. [Pubmed]
    Trempe J.F., Brown N.R., Noble M.E., Endicott J.A. (2011) A new crystal form of Lys48-linked diubiquitin. Acta Crystallogr. Sect F Struct. Biol. Cryst. Commun. 66(Pt 9):994-8. [Pubmed]
    Riedinger C., Boehringer J., Trempe J.F., Lowe E.D., Brown N.R., Gehring K., Noble M.E., Gordon C., Endicott J.A. (2010) Structure of Rpn10 and its interactions with polyubiquitin chains and the proteasome subunit Rpn12. J. Biol. Chem. 285(44):33992-400. [Pubmed]
    Banerji S., Hide B.R., James J.R., Noble M.E., Jackson D.G. (2010) Distinctive properties of the hyaluronan-binding domain in the lymphatic endothelial receptor Lyve-1 and their implications for receptor function. J. Biol. Chem. 285(14):10724-35. [Pubmed]
    Abuhammad A.M., Lowe E.D., Fullam E., Noble M., Garman E.F., Sim E. (2010) Probing the architecture of the Mycobacterium marinum arylamine N-acetyltransferase active site. Protein Cell. 1(4):384-92. [Pubmed]
    Echalier A., Endicott J.A., Noble M.E. (2010) Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim. Biophys. Acta. 1804(3):511-9. [Pubmed]
    Takaki T., Echalier A., Brown N.R., Hunt T., Endicott J.A., Noble M.E. (2009) The structure of CDK4/cyclin D3 has implications for models of CDK activation. Proc. Natl. Acad. Sci. U. S. A. 106(11):4171-6. [Pubmed]
    Riedinger C., Endicott J.A., Kemp S.J., Smyth L.A., Watson A., Valeur E., Golding B.T., Griffin R.J., Hardcastle I.R., Noble M.E., McDonnell J.M. (2008) Analysis of chemical shift changes reveals the binding modes of isoindolinone inhibitors of the MDM2-p53 interaction. J. Am. Chem. Soc. 130(47):16038-44. [Pubmed]
    Lorenz S., Vakonakis I., Lowe E.D., Campbell I.D., Noble M.E., Hoellerer M.K. (2008) Structural analysis of the interactions between paxillin LD motifs and alpha-parvin. Structure. 16(10):1521-31. [Pubmed]
    Lack N., Lowe E.D., Liu J., Eltis L.D., Noble M.E., Sim E., Westwood I.M. (2008) Structure of HsaD, a steroid-degrading hydrolase, from Mycobacterium tuberculosis. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 64(Pt 1):2-7. [Pubmed]
    Merckx A., Echalier A., Langford K., Sicard A., Langsley G., Joore J., Doerig C., Noble M., Endicott J. Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design. Structure 16(2):228-38. [Pubmed]
    Sim E., Sandy J., Evangelopoulos D., Fullam E., Bhakta S., Westwood I., Krylova A., Lack N., Noble M. Arylamine N-acetyltransferases in mycobacteria. Curr. Drug Metab. 9(6):510-9. [Pubmed]
    Fullam E., Westwood I.M., Anderton M.C., Lowe E.D., Sim E., Noble M.E. (2008) Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase. J. Mol. Biol. 375(1):178-91. [Pubmed]
    Higman V.A., Blundell C.D., Mahoney D.J., Redfield C., Noble M.E., Day A.J. (2007) Plasticity of the TSG-6 HA-binding loop and mobility in the TSG-6-HA complex revealed by NMR and X-ray crystallography. J. Mol. Biol. 371(3):669-84. [Pubmed]
    Marchetti F., Sayle K.L., Bentley J., Clegg W., Curtin N.J., Endicott J.A., Golding B.T., Griffin R.J., Haggerty K., Harrington R.W., Mesguiche V., Newell D.R., Noble M.E., Parsons R.J., Pratt D.J., Wang L.Z., Hardcastle I.R. (2007) Structure-based design of 2-arylamino-4-cyclohexylmethoxy-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinase 2. Org. Biomol. Chem. 5(10):1577-85. [Pubmed]
    Gruber J., Zawaira A., Saunders R., Barrett C.P., Noble M.E. (2007) Computational analyses of the surface properties of protein-protein interfaces. Acta Crystallogr. D Biol. Crystallogr. 63(Pt 1):50-7. [Pubmed]
    Welburn J.P., Tucker J.A., Johnson T., Lindert L., Morgan M., Willis A., Noble M.E., Endicott J.A. (2007) How tyrosine 15 phosphorylation inhibits the activity of cyclin-dependent kinase 2-cyclin A. J. Biol. Chem. 282(5):3173-81. [Pubmed]
    Wang C.J., Hagemeier C., Rahman N., Lowe E., Noble M., Coughtrie M., Sim E., Westwood I. (2007) Molecular cloning, characterisation and ligand-bound structure of an azoreductase from Pseudomonas aeruginosa. J. Mol. Biol. 373(5):1213-28. [Pubmed]
    Banerji S., Wright A.J., Noble M., Mahoney D.J., Campbell I.D., Day A.J., Jackson D.G. (2007) Structures of the Cd44-hyaluronan complex provide insight into a fundamental carbohydrate-protein interaction. Nat. Struct. Mol. Biol. 14(3):234-9. [Pubmed]
    Pratt D.J., Bentley J., Jewsbury P., Boyle F.T., Endicott J.A., Noble M.E. (2006) Dissecting the determinants of cyclin-dependent kinase 2 and cyclin-dependent kinase 4 inhibitor selectivity. J. Med. Chem. 49(18):5470-7. [Pubmed]
    Cheng K.Y., Noble M.E., Skamnaki V., Brown N.R., Lowe E.D., Kontogiannis L., Shen K., Cole P.A., Siligardi G., Johnson L.N. (2006) The role of the phospho-CDK2/cyclin A recruitment site in substrate recognition. J. Biol. Chem. 281(32):23167-79. [Pubmed]
    Griffin R.J., Henderson A., Curtin N.J., Echalier A., Endicott J.A., Hardcastle I.R., Newell D.R., Noble M.E., Wang L.Z., Golding B.T. (2006) Searching for cyclin-dependent kinase inhibitors using a new variant of the cope elimination. J. Am. Chem. Soc. 128(18):6012-3. [Pubmed]
    Lowe E.D., Hasan N., Trempe J.F., Fonso L., Noble M.E., Endicott J.A., Johnson L.N., Brown N.R. (2006) Structures of the Dsk2 UBL and UBA domains and their complex. Acta Crystallogr. D Biol. Crystallogr. 62(Pt 2):177-88. [Pubmed]
    Sandy J., Holton S., Fullam E., Sim E., Noble M. (2005) Binding of the anti-tubercular drug isoniazid to the arylamine N-acetyltransferase protein from Mycobacterium smegmatis. Protein Sci. 14(3):775-82. [Pubmed]
    Noble M., Barrett P., Endicott J., Johnson L., McDonnell J., Robertson G., Zawaira A. (2005) Exploiting structural principles to design cyclin-dependent kinase inhibitors. Biochim. Biophys. Acta. 1754(1-2):58-64. [Pubmed]
    Holton S., Dairou J., Sandy J., Rodrigues-Lima F., Dupret J.M., Noble M.E., Sim E. (2005) Structure of Mesorhizobium loti arylamine N-acetyltransferase 1. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 61(Pt 1):14-6. [Pubmed]
    Macdonald N., Welburn J.P., Noble M.E., Nguyen A., Yaffe M.B., Clynes D., Moggs J.G., Orphanides G., Thomson S., Edmunds J.W., Clayton A.L., Endicott J.A., Mahadevan L.C. (2005) Molecular basis for the recognition of phosphorylated and phosphoacetylated histone h3 by 14-3-3. Mol. Cell. 20(2):199-211. [Pubmed]
    Trempe J.F., Brown N.R., Lowe E.D., Gordon C., Campbell I.D., Noble M.E., Endicott J.A. (2005) Mechanism of Lys48-linked polyubiquitin chain recognition by the Mud1 UBA domain. EMBO J. 2005 24(18):3178-89. [Pubmed]
    Sandy J., Mushtaq A., Holton S.J., Schartau P., Noble M.E., Sim E. (2005) Investigation of the catalytic triad of arylamine N-acetyltransferases: essential residues required for acetyl transfer to arylamines. Biochem. J. 390(Pt 1):115-23. [Pubmed]
    Barrett C.P., Noble M.E. (2005) Dynamite extended: two new services to simplify protein dynamic analysis. Bioinformatics. 21(14):3174-5. [Pubmed]
    Barrett C.P., Noble M.E. (2005) Molecular motions of human cyclin-dependent kinase 2. J. Biol. Chem. 280(14):13993-4005. [Pubmed]
    Barrett C.P., Hall B.A., Noble M.E. (2004) Dynamite: a simple way to gain insight into protein motions. Acta Crystallogr. D Biol. Crystallogr. 60(Pt 12 Pt 1):2280-7. [Pubmed]
    Westwood I.M., Holton S.J., Rodrigues-Lima F., Dupret J.M., Bhakta S., Noble M.E., Sim E. (2005) Expression, purification, characterization and structure of Pseudomonas aeruginosa arylamine N-acetyltransferase. Biochem. J. 385(Pt 2):605-12. [Pubmed]
    Pratt D.J., Endicott J.A., Noble M.E. (2004) The role of structure in kinase-targeted inhibitor design. Curr. Opin. Drug Discov. Devel. 7(4):428-36. [Pubmed]
    Hardcastle I.R., Arris C.E., Bentley J., Boyle F.T., Chen Y., Curtin N.J., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Jewsbury P., Menyerol J., Mesguiche V., Newell D.R., Noble M.E., Pratt D.J., Wang L.Z., Whitfield H.J. (2004) N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2. J. Med. Chem. 47(15):3710-22. [Pubmed]
    Noble M.E., Endicott J.A., Johnson L.N. (2004) Protein kinase inhibitors: insights into drug design from structure. Science. 303(5665):1800-5. [Pubmed]
    Hoellerer M.K., Noble M.E., Labesse G., Campbell I.D., Werner J.M., Arold S.T. (2003) Molecular recognition of paxillin LD motifs by the focal adhesion targeting domain. Structure 11(10):1207-17. [Pubmed]
    Sayle K.L., Bentley J., Boyle F.T., Calvert A.H., Cheng Y., Curtin N.J., Endicott J.A., Golding B.T., Hardcastle I.R., Jewsbury P., Mesguiche V., Newell D.R., Noble M.E., Parsons R.J., Pratt D.J., Wang L.Z., Griffin R.J. (2003) Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 13(18):3079-82. [Pubmed]
    Teriete P., Banerji S., Noble M., Blundell C.D., Wright A.J., Pickford A.R., Lowe E., Mahoney D.J., Tammi M.I., Kahmann J.D., Campbell I.D., Day A.J., Jackson D.G. (2004) Structure of the regulatory hyaluronan binding domain in the inflammatory leukocyte homing receptor CD44. Mol. Cell. 13(4):483-96. [Pubmed]
    Mesguiche V., Parsons R.J., Arris C.E., Bentley J., Boyle F.T., Curtin N.J., Davies T.G., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Jewsbury P., Johnson L.N., Newell D.R., Noble M.E., Wang L.Z., Hardcastle I.R. (2003) 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2. Bioorg. Med. Chem. Lett. 13(2):217-22. [Pubmed]
    Mettey Y., Gompel M., Thomas V., Garnier M., Leost M., Ceballos-Picot I., Noble M., Endicott J., Vierfond J.M., Meijer L. (2003) Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects. J. Med. Chem. 46(2):222-36. [Pubmed]
    Sim E., Pinter K., Mushtaq A., Upton A., Sandy J., Bhakta S., Noble M. (2003) Arylamine N-acetyltransferases: a pharmacogenomic approach to drug metabolism and endogenous function. Biochem. Soc. Trans. 31(Pt 3):615-9. [Pubmed]
    Kawamura A., Sandy J., Upton A., Noble M., Sim E. (2003) Structural investigation of mutant Mycobacterium smegmatis arylamine N-acetyltransferase: a model for a naturally occurring functional polymorphism in Mycobacterium tuberculosis arylamine N-acetyltransferase. Protein Expr. Purif. 27(1):75-84. [Pubmed]
    Holton S., Merckx A., Burgess D., Doerig C., Noble M., Endicott J. (2003) Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure 11(11):1329-37. [Pubmed]
    Leng X., Noble M., Adams P.D., Qin J., Harper J.W. (2002) Reversal of growth suppression by p107 via direct phosphorylation by cyclin D1/cyclin-dependent kinase 4. Mol. Cell Biol. 22(7):2242-54. [Pubmed]
    Sandy J., Mushtaq A., Kawamura A., Sinclair J., Sim E., Noble M. (2002) The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid. J. Mol. Biol. 318(4):1071-83. [Pubmed]
    Lowe E.D., Tews I., Cheng K.Y., Brown N.R., Gul S., Noble M.E., Gamblin S.J., Johnson L.N. (2002) Specificity determinants of recruitment peptides bound to phospho-CDK2/cyclin A. Biochemistry 41(52):15625-34. [Pubmed]
    Davies T.G., Bentley J., Arris C.E., Boyle F.T., Curtin N.J., Endicott J.A., Gibson A.E., Golding B.T., Griffin R.J., Hardcastle I.R., Jewsbury P., Johnson L.N., Mesguiche V., Newell D.R., Noble M.E., Tucker J.A., Wang L., Whitfield H.J. (2002) Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor. Nat. Struct. Biol. 9(10):745-9. [Pubmed]
    Davies T.G., Pratt D.J., Endicott J.A., Johnson L.N., Noble M.E. (2002) Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol. Ther. 93(2-3):125-33. [Pubmed]
    Johnson L.N., De Moliner E., Brown N.R., Song H., Barford D., Endicott J.A., Noble M.E. (2002) Structural studies with inhibitors of the cell cycle regulatory kinase cyclin-dependent protein kinase 2. Pharmacol. Ther. 93(2-3):113-24. [Pubmed]
    Gibson A.E., Arris C.E., Bentley J., Boyle F.T., Curtin N.J., Davies T.G., Endicott J.A., Golding B.T., Grant S., Griffin R.J., Jewsbury P., Johnson L.N., Mesguiche V., Newell D.R., Noble M.E., Tucker J.A., Whitfield H.J. (2002) Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives. J. Med. Chem. 45(16):3381-93. [Pubmed]
    Arold S.T., Hoellerer M.K., Noble M.E. (2002) The structural basis of localization and signaling by the focal adhesion targeting domain. Structure (3):319-27. [Pubmed]
    Lawrie A.M., Tito P., Hernandez H., Brown N.R., Robinson C.V., Endicott J.A., Noble M.E., Johnson L.N. (2001) Xenopus phospho-CDK7/cyclin H expressed in baculoviral-infected insect cells. Protein Expr. Purif. 23(2):252-60. [Pubmed]
    Song H., Hanlon N., Brown N.R., Noble M.E., Johnson L.N., Barford D. (2001) Phosphoprotein-protein interactions revealed by the crystal structure of kinase-associated phosphatase in complex with phosphoCDK2. Mol. Cell. 7(3):615-26. [Pubmed]
    Davies T.G., Tunnah P., Meijer L., Marko D., Eisenbrand G., Endicott J.A., Noble M.E. (2001) Inhibitor binding to active and inactive CDK2: the crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 9(5):389-97. [Pubmed]
    Arold S.T., Ulmer T.S., Mulhern T.D., Werner J.M., Ladbury J.E., Campbell I.D., Noble M.E. (2001) The role of the Src homology 3-Src homology 2 interface in the regulation of Src kinases. J. Biol. Chem. 276(20):17199-205. [Pubmed]
    Sim E., Payton M., Noble M., Minchin R. (2000) An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and procaryotes. Hum. Mol. Genet. 9(16):2435-41. [Pubmed]
    Legraverend M., Tunnah P., Noble M., Ducrot P., Ludwig O., Grierson D.S., Leost M., Meijer L., Endicott J. (2000) Cyclin-dependent kinase inhibition by new C-2 alkynylated purine derivatives and molecular structure of a CDK2-inhibitor complex. J. Med. Chem. 43(7):1282-92. [Pubmed]
    Arris C.E., Boyle F.T., Calvert A.H., Curtin N.J., Endicott J.A., Garman E.F., Gibson A.E., Golding B.T., Grant S., Griffin R.J., Jewsbury P., Johnson L.N., Lawrie A.M., Newell D.R., Noble M.E., Sausville E.A., Schultz R., Yu W. (2000) Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles. J. Med. Chem. 43(15):2797-804. [Pubmed]
    Sinclair J.C., Sandy J., Delgoda R., Sim E., Noble M.E. (2000) Structure of arylamine N-acetyltransferase reveals a catalytic triad. Nat. Struct. Biol. 7(7):560-4. [Pubmed]
    Endicott J.A., Noble M.E., Tucker J.A. (1999) Cyclin-dependent kinases: inhibition and substrate recognition. Curr. Opin. Struct. Biol. 9(6):738-44. [Pubmed]
    Hoessel R., Leclerc S., Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol. 1(1):60-7. [Pubmed]
    Brown N.R., Noble M.E., Endicott J.A., Johnson L.N. (1999) The structural basis for specificity of substrate and recruitment peptides for cyclin-dependent kinases. Nat. Cell. Biol. 1(7):438-43. [Pubmed]
    Hoessel R., Leclerc S.,Endicott J.A., Nobel M.E., Lawrie A., Tunnah P., Leost M., Damiens E., Marie D., Marko D., Niederberger E., Tang W., Eisenbrand G., Meijer L. (1999) Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat. Cell. Biol. 1(1):60-7. [Pubmed]
    Skamnaki V.T., Owen D.J., Noble M.E., Lowe E.D., Lowe G., Oikonomakos N.G., Johnson L.N. (1999) Catalytic mechanism of phosphorylase kinase probed by mutational studies. Biochemistry 38(44):14718-30. [Pubmed]
    Noble M.E., Endicott J.A. (1999) Chemical inhibitors of cyclin-dependent kinases: insights into design from X-ray crystallographic studies. Pharmacol. Ther. 82(2-3):269-78. [Pubmed]
    Owen D.J., Vallis Y., Noble M.E., Hunter J.B., Dafforn T.R., Evans P.R., McMahon H.T. (1999) A structural explanation for the binding of multiple ligands by the alpha-adaptin appendage domain. Cell 97(6):805-15. [Pubmed]
    Brown N.R., Noble M.E., Lawrie A.M., Morris M.C., Tunnah P., Divita G., Johnson L.N., Endicott J.A. (1999) Effects of phosphorylation of threonine 160 on cyclin-dependent kinase 2 structure and activity. J. Biol. Chem. 274(13):8746-56. [Pubmed]
    Johnson L.N., Lowe E.D., Noble M.E., Owen D.J. (1998) The Eleventh Datta Lecture. The structural basis for substrate recognition and control by protein kinases. FEBS Lett. 430(1-2):1-11. [Pubmed]
    Endicott J.A., Noble M.E. (1998) Structural principles in cell-cycle control: beyond the CDKs. Structure 6(5):535-41. [Pubmed]
    Sinclair J.C., Delgoda R., Noble M.E., Jarmin S., Goh N.K., Sim E. (1998) Purification, characterization, and crystallization of an N-hydroxyarylamine O-acetyltransferase from Salmonella typhimurium. Protein Expr. Purif. 12(3):371-80.[Pubmed]
    Gregoriou M., Noble M.E., Watson K.A., Garman E.F., Krulle T.M., de la Fuente C., Fleet G.W., Oikonomakos N.G., Johnson L.N. (1998) The structure of a glycogen phosphorylase glucopyranose spirohydantoin complex at 1.8 A resolution and 100 K: the role of the water structure and its contribution to binding. Protein Sci. 7(4):915-27. [Pubmed]
    Noble M.E., Endicott J.A., Brown N.R., Johnson L.N. (1997) The cyclin box fold: protein recognition in cell-cycle and transcription control.Trends Biochem. Sci. 22(12):482-7. [Pubmed]
    Lowe E.D., Noble M.E., Skamnaki V.T., Oikonomakos N.G., Owen D.J., Johnson L.N. (1997) The crystal structure of a phosphorylase kinase peptide substrate complex: kinase substrate recognition. EMBO J. 16(22):6646-58. [Pubmed]
    Lawrie A.M., Noble M.E., Tunnah P., Brown N.R., Johnson L.N., Endicott J.A. (1997) Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat. Struct. Biol. 4(10):796-801. [Pubmed]
    Johnson L.N., Barford D., Owen D.J., Noble M.E., Garman E.F. (1997) From phosphorylase to phosphorylase kinase. Adv. Second Messenger Phosphoprotein Res. 31:11-28. [Pubmed]
    Johnson L.N., Noble M.E., Owen D.J. (1996) Active and inactive protein kinases: structural basis for regulation. Cell 85(2):149-58. [Pubmed]
    Brown N.R., Noble M.E., Endicott J.A., Garman E.F., Wakatsuki S., Mitchell E., Rasmussen B., Hunt T., Johnson L.N. (1995) The crystal structure of cyclin A. Structure 3(11):1235-47. [Pubmed]
    Bourne Y., Arvai A.S., Bernstein S.L., Watson M.H., Reed S.I., Endicott J.E., Noble M.E., Johnson L.N., Tainer J.A. (1995) Crystal structure of the cell cycle-regulatory protein suc1 reveals a beta-hinge conformational switch. Proc. Natl. Acad. Sci. U. S. A. 92(22):10232-6. [Pubmed]
    Timms J.F., Noble M.E., Gregoriou M. (1995) An investigation of the role of Glu-842, Glu-844 and His-846 in the function of the cytoplasmic domain of the epidermal growth factor receptor. Biochem. J. 308 ( Pt 1):219-29. [Pubmed]
    Owen D.J., Noble M.E., Garman E.F., Papageorgiou A.C., Johnson L.N. (1995) Two structures of the catalytic domain of phosphorylase kinase: an active protein kinase complexed with substrate analogue and product. Structure 3(5):467-82. [Pubmed]
    Endicott J.A., Noble M.E., Garman E.F., Brown N., Rasmussen B., Nurse P., Johnson L.N. (1995) The crystal structure of p13suc1, a p34cdc2-interacting cell cycle control protein. EMBO J. 14(5):1004-14. [Pubmed]
    Owen D.J., Papageorgiou A.C., Garman E.F., Noble M.E., Johnson L.N. (1995) Expression, purification and crystallisation of phosphorylase kinase catalytic domain. J. Mol. Biol. 246(3):374-81. [Pubmed]
    Kishan R., Zeelen J.P., Noble M.E., Borchert T.V., Mainfroid V., Goraj K., Martial J.A., Wierenga R.K. (1994) Modular mutagenesis of a TIM-barrel enzyme: the crystal structure of a chimeric E. coli TIM having the eighth beta alpha-unit replaced by the equivalent unit of chicken TIM. (1994) Protein Eng. 7(8):945-51.[Pubmed]
    Kishan K.V., Zeelen J.P., Noble M.E., Borchert T.V., Wierenga R.K. (1994) Comparison of the structures and the crystal contacts of trypanosomal triosephosphate isomerase in four different crystal forms. Protein Sci. 3(5):779-87. [Pubmed]
    Noble M.E., Cleasby A., Johnson L.N., Egmond M.R., Frenken L.G. (1994) Analysis of the structure of Pseudomonas glumae lipase. Protein Eng. 7(4):559-62. [Pubmed]
    Mainfroid V., Goraj K., Rentier-Delrue F., Houbrechts A., Loiseau A., Gohimont A.C., Noble M.E., Borchert T.V., Wierenga R.K., Martial J.A. (1993) Replacing the (beta alpha)-unit 8 of E. coli TIM with its chicken homologue leads to a stable and active hybrid enzyme. Protein Eng. 6(8):893-900. [Pubmed]
    Noble M.E., Cleasby A., Johnson L.N., Egmond M.R., Frenken L.G. (1993) The crystal structure of triacylglycerol lipase from Pseudomonas glumae reveals a partially redundant catalytic aspartate. FEBS Lett. 331(1-2):123-8. [Pubmed]
    Noble M.E., Zeelen J.P., Wierenga R.K. (1993) Structures of the "open" and "closed" state of trypanosomal triosephosphate isomerase, as observed in a new crystal form: implications for the reaction mechanism. Proteins 16(4):311-26. [Pubmed]
    Noble M.E., Zeelen J.P., Wierenga R.K., Mainfroid V., Goraj K., Gohimont A.C., Martial J.A. (1993) Structure of triosephosphate isomerase from Escherichia coli determined at 2.6 A resolution. Acta Crystallogr. D Biol. Crystallogr. 49(Pt 4):403-17. [Pubmed]
    Noble M.E., Musacchio A., Saraste M., Courtneidge S.A., Wierenga R.K. (1993) Crystal structure of the SH3 domain in human Fyn; comparison of the three-dimensional structures of SH3 domains in tyrosine kinases and spectrin. EMBO J. 12(7):2617-24. [Pubmed]
    Borchert T.V., Pratt K., Zeelen J.P., Callens M., Noble M.E., Opperdoes F.R., Michels P.A., Wierenga R.K. (1993) Overexpression of trypanosomal triosephosphate isomerase in Escherichia coli and characterisation of a dimer-interface mutant. Eur. J. Biochem. 211(3):703-10. [Pubmed]
    Musacchio A., Noble M., Pauptit R., Wierenga R., Saraste M. (1992) Crystal structure of a Src-homology 3 (SH3) domain. Nature 359(6398):851-5. [Pubmed]
    Wierenga R.K., Borchert T.V., Noble M.E. (1992) Crystallographic binding studies with triosephosphate isomerases: conformational changes induced by substrate and substrate-analogues. FEBS Lett. 307(1):34-9. [Pubmed]
    Wierenga R.K., Noble M.E., Davenport R.C. (1992) Comparison of the refined crystal structures of liganded and unliganded chicken, yeast and trypanosomal triosephosphate isomerase. J. Mol. Biol. 224(4):1115-26. [Pubmed]
    Noble M.E., Verlinde C.L., Groendijk H., Kalk K.H., Wierenga R.K., Hol W.G. (1991) Crystallographic and molecular modeling studies on trypanosomal triosephosphate isomerase: a critical assessment of the predicted and observed structures of the complex with 2-phosphoglycerate. J. Med. Chem. 34(9):2709-18. [Pubmed]
    Wierenga R.K., Noble M.E., Vriend G., Nauche S., Hol W.G. (1991) Refined 1.83 A structure of trypanosomal triosephosphate isomerase crystallized in the presence of 2.4 M-ammonium sulphate. A comparison with the structure of the trypanosomal triosephosphate isomerase-glycerol-3-phosphate complex. J. Mol. Biol. 220(4):995-1015. [Pubmed]
    Verlinde C.L., Noble M.E., Kalk K.H., Groendijk H., Wierenga R.K., Hol W.G. (1991) Anion binding at the active site of trypanosomal triosephosphate isomerase. Monohydrogen phosphate does not mimic sulphate. Eur. J. Biochem. 198(1):53-7. [Pubmed]
    Noble M.E., Wierenga R.K., Lambeir A.M., Opperdoes F.R., Thunnissen A.M., Kalk K.H., Groendijk H., Hol W.G. (1991) The adaptability of the active site of trypanosomal triosephosphate isomerase as observed in the crystal structures of three different complexes. Proteins 10(1):50-69. [Pubmed]
    Wierenga R.K., Noble M.E., Postma J.P., Groendijk H., Kalk K.H., Hol W.G., Opperdoes F.R. (1991) The crystal structure of the "open" and the "closed" conformation of the flexible loop of trypanosomal triosephosphate isomerase. Proteins 10(1):33-49. [Pubmed]
Search

only search SBL website
Highlights

February 2014
JBC Best paper of the year 2013 awarded to Pr. Rick Lewis
Read more...

January 2014
2014 is the year of Crystallography
Read more...

January 2014
CCP4 Study Weekend
3-5th of January, Nottingham University Read more...

Contact Info

Newcastle Structural Biology Laboratory
ICAMB, Medical School University of Newcastle Framlington place NE2 4HH, Newcastle upon Tyne, UK

Phone: (191) 222-7436
Fax: (191) 222-7424